This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Stuart A. Lipton, MD, PhD
Department of Neurology Beth Israel Hospital and Children's Hospital Harvard Medical School Boston, MA 02115

Nina F. Schor, MD, PhD
Division of Child Neurology University of Pittsburgh School of Medicine Pittsburgh, PA 15261

Arch Neurol. 1987;44(7):691-692.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—We thank Drs Levine and Welch for their interest, for their letter, and for sharing with us a preprint of their article¹ on the subject of the lupuslike anticoagulant or lupus inhibitor and its presumptive association with cerebral infarcts. Our recent publication² agrees with the concluding paragraph of their letter: the lupuslike anticoagulant appears to be associated with an increased risk for stroke, and other factors (perhaps even those as yet unknown) may contribute to this risk. Since it is theoretically impossible to ever know all of the potential risk factors for stroke, their last point—that it is unclear if the presence of the lupuslike anticoagulant alone, in the absence of other risk factors, can increase the probability of cerebral infarction—seems obvious. Our case report presented a young (31-year-old) man with a stroke who had a lupuslike anticoagulant in the absence of other known risk factors for infarction; . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?